Manejo hemostático complejo en paciente con hemofilia adquirida.

Acquired haemophilia A (AHA) is a rare clinical disease of autoimmune origin brought about by circulating autoantibodies that inhibit FVIII activity. Acute-onset haemorrhagic manifestations present in patients with no previous history of haemorrhage. Haemostatic treatment is currently based on the use of recombinant activated factor VII bypass agents (rFVIIa) or activated prothrombin complex concentrates (CCPa), which have been demonstrated to have high efficacy rates in published trials and registries. Thanks to the availability of these agents, early mortality due to this disease has decreased in recent years. In patients with refractory bleeding requiring haemostatic treatment, other causes that can explain the clinical picture must first be ruled out. As such, we are presenting a clinical case of a male patient diagnosed with AHA, whose haemorrhagic condition was treated using bypass agents, and who responded well following correction of his fibrinogen and factor XIII levels by administering the corresponding blood products. [ABSTRACT FROM AUTHOR]